Clinical Trial Update: This is a Single Ascending Dose Tolerance Study [Phase 1]

View source ↗

Summary

Abbott reported termination of a Phase 1 single ascending dose tolerance study in cognitive disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders

Snippet

Sponsor: Abbott | Conditions: Cognition Disorders | Phase 1 | Status: TERMINATED